Information Collection; Affirmative Procurement of Biobased Procurements Under Services and Construction Contracts, 40769-40770 [2017-18105]
Download as PDF
Federal Register / Vol. 82, No. 165 / Monday, August 28, 2017 / Notices
and Receiverships, Attention:
Receivership Oversight Department
34.6, 1601 Bryan Street, Dallas, TX
75201.
No comments concerning the
termination of this receivership will be
considered which are not sent within
this time frame.
Dated: August 23, 2017.
Federal Deposit Insurance Corporation.
DEPARTMENT OF DEFENSE
GENERAL SERVICES
ADMINISTRATION
NATIONAL AERONAUTICS AND
SPACE ADMINISTRATION
[OMB Control No. 9000–0180; Docket No.
2017–0053; Sequence 12]
[FR Doc. 2017–18156 Filed 8–25–17; 8:45 am]
Information Collection; Affirmative
Procurement of Biobased
Procurements Under Services and
Construction Contracts
BILLING CODE 6714–01–P
AGENCY:
Robert E. Feldman,
Executive Secretary.
FEDERAL DEPOSIT INSURANCE
CORPORATION
asabaliauskas on DSKBBXCHB2PROD with NOTICES
Notice to All Interested Parties of the
Termination of the Receivership of
10301—First Suburban National Bank,
Maywood, Illinois
Notice is hereby given that the Federal
Deposit Insurance Corporation (FDIC) as
Receiver for First Suburban National
Bank, Maywood, Illinois (‘‘the
Receiver’’) intends to terminate its
receivership for said institution. The
FDIC was appointed Receiver of First
Suburban National Bank on October 22,
2010. The liquidation of the
receivership assets has been completed.
To the extent permitted by available
funds and in accordance with law, the
Receiver will be making a final dividend
payment to proven creditors.
Based upon the foregoing, the
Receiver has determined that the
continued existence of the receivership
will serve no useful purpose.
Consequently, notice is given that the
receivership shall be terminated, to be
effective no sooner than thirty days after
the date of this notice. If any person
wishes to comment concerning the
termination of the receivership, such
comment must be made in writing and
sent within thirty days of the date of
this notice to: Federal Deposit Insurance
Corporation, Division of Resolutions
and Receiverships, Attention:
Receivership Oversight Department
34.6, 1601 Bryan Street, Dallas, TX
75201.
No comments concerning the
termination of this receivership will be
considered which are not sent within
this time frame.
Dated August 22, 2017.
Federal Deposit Insurance Corporation.
Robert E. Feldman,
Executive Secretary.
[FR Doc. 2017–18109 Filed 8–25–17; 8:45 am]
BILLING CODE 6714–01–P
VerDate Sep<11>2014
18:45 Aug 25, 2017
Jkt 241001
Department of Defense (DOD),
General Services Administration (GSA),
and National Aeronautics and Space
Administration (NASA).
ACTION: Notice of request for public
comments regarding an extension to an
existing OMB clearance.
Under the provisions of the
Paperwork Reduction Act, the
Regulatory Secretariat Division (MVCB)
will be submitting to the Office of
Management and Budget (OMB) a
request to review and approve an
extension of a previously approved
information collection requirement
regarding Biobased Procurements.
DATES: Submit comments on or before
October 27, 2017.
ADDRESSES: Submit comments
identified by Information Collection
9000–0180, Affirmative Procurement of
Biobased Procurements Under Services
and Construction Contracts, by any of
the following methods:
• Regulations.gov: https://
www.regulations.gov. Submit comments
via the Federal eRulemaking portal by
searching the OMB control number
9000–0180. Select the link ‘‘Comment
Now’’ that corresponds with
‘‘Information Collection 9000–0180,
Affirmative Procurement of Biobased
Procurements Under Services and
Construction Contracts. Follow the
instructions provided on the screen.
Please include your name, company
name (if any), and ‘‘Information
Collection 9000–0180, ‘‘Affirmative
Procurement of Biobased Procurements
Under Services and Construction
Contracts’’ on your attached document.
• Mail: General Services
Administration, Regulatory Secretariat
Division (MVCB), 1800 F Street NW.,
Washington, DC 20405. ATTN: Ms.
Sosa/IC 9000–0180, Biobased
Procurements.
Instructions: Please submit comments
only and cite Information Collection
9000–0180, Affirmative Procurement of
Biobased Procurements Under Services
and Construction Contracts. Comments
received generally will be posted
SUMMARY:
PO 00000
Frm 00026
Fmt 4703
Sfmt 4703
40769
without change to https://
www.regulations.gov, including any
personal and/or business confidential
information provided. To confirm
receipt of your comment(s), please
check www.regulations.gov,
approximately two to three days after
submission to verify posting (except
allow 30 days for posting of comments
submitted by mail).
FOR FURTHER INFORMATION CONTACT: Mr.
Charles Gray, Procurement Analyst,
Office of Governmentwide Acquisition
Policy, at telephone 703–795–6328, or
email charles.gray@gsa.gov.
SUPPLEMENTARY INFORMATION:
A. Purpose
Federal Acquisition Regulation clause
52.223–2, Affirmative Procurement of
Biobased Products Under Service and
Construction Contracts, requires prime
contractors to report annually the
product types and dollar values of U.S.
Department of Agriculture (USDA)designated biobased products purchased
to the System for Award Management
(SAM) Web site. The information
reported by prime contractors enables
Federal agencies to report annually to
the Office of Federal Procurement
Policy (OFPP) concerning actions taken
to implement and measure progress in
carrying out the preference for biobased
products required under section 9002 of
the Farm Security and Rural Investment
Act of 2002, codified at 7 U.S.C. 8102.
B. Annual Reporting Burden
To determine the number of
contractors performing construction and
service contracts that may involve the
purchase of USDA-designated biobased
products, fiscal year 2016 data in the
Federal Procurement Data System
(FPDS) was reviewed to calculate the
number entities with unique DUNS
numbers that were awarded contracts
for the following selected Product
Services Codes: A—Research and
Development; F—Natural Resources
Management; J—Maintenance, Repair,
and Rebuilding of Equipment; M—
Operation of Government-Owned
Facility; S—Utilities and Housekeeping
Services; T—Photographic, Mapping,
Printing, and Publication Services; Y—
Construction of Structures and
Facilities; and Z—Maintenance, Repair
or Alteration of Real Property. The
clause at FAR 52.223–2 will apply to the
majority of the contract actions in the
selected PSCs
The estimated total burden is as
follows:
Respondents: 51,457.
Responses per Respondent: 5.
Total Annual Responses: 257,285.
E:\FR\FM\28AUN1.SGM
28AUN1
40770
Federal Register / Vol. 82, No. 165 / Monday, August 28, 2017 / Notices
Hours per Response: 5.
Total Burden Hours: 1,286,425.
Affected Public: Businesses or other
for-profit and not-for-profit institutions.
Frequency: Annually.
C. Public Comments
Public comments are particularly
invited on: Whether this collection of
information is necessary for the proper
performance of functions of the FAR,
and whether it will have practical
utility; whether our estimate of the
public burden of this collection of
information is accurate, and based on
valid assumptions and methodology;
ways to enhance the quality, utility, and
clarity of the information to be
collected; and ways in which we can
minimize the burden of the collection of
information on those who are to
respond, through the use of appropriate
technological collection techniques or
other forms of information technology.
Obtaining Copies of Proposals:
Requesters may obtain a copy of the
information collection documents from
the General Services Administration,
Regulatory Secretariat Division (MVCB),
1800 F Street NW., Washington, DC
20405, telephone 202–501–4755. Please
cite OMB Control No. 9000–0180,
Affirmative Procurement of Biobased
Procurements Under Services and
Construction Contracts, in all
correspondence.
Dated: August 22, 2017.
Lorin S. Curit,
Director, Federal Acquisition Policy Division,
Office of Government-wide Acquisition
Policy, Office of Acquisition Policy, Office
of Government-wide Policy.
[FR Doc. 2017–18105 Filed 8–25–17; 8:45 am]
BILLING CODE 6820–EP–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[Docket No. FDA–2017–N–0001]
Cellular, Tissue, and Gene Therapies
Advisory Committee; Notice of Meeting
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) announces a
forthcoming public advisory committee
meeting of the Cellular, Tissue, and
Gene Therapies Advisory Committee
(CTGTAC). The general function of the
committee is to provide advice and
recommendations to the Agency on
FDA’s regulatory issues. The meeting
will be open to the public.
asabaliauskas on DSKBBXCHB2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
18:45 Aug 25, 2017
Jkt 241001
FDA White Oak Campus,
10903 New Hampshire Ave., Bldg. 31
Conference Center, the Great Room (Rm.
1503) Silver Spring, MD 20993–0002.
For those unable to attend in person,
the meeting will also be Webcast and
will be available at the following link:
https://collaboration.fda.gov/
ctgtac101217. Answers to commonly
asked questions including information
regarding special accommodations due
to a disability, visitor parking, and
transportation may be accessed at:
https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm408555.htm.
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
Prabhakara L. Atreya or Denise Royster,
Center for Biologics Evaluation and
Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 71, Rm. 6306, Silver Spring,
MD 20993–0002, 240–402–8006,
prabhakara.atreya@fda.hhs.gov and
240–402–8158, denise.royster@
fda.hhs.gov, or FDA Advisory
Committee Information Line, 1–800–
741–8138 (301–443–0572 in the
Washington, DC area). A notice in the
Federal Register about last minute
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly
enough to provide timely notice.
Therefore, you should always check the
Agency’s Web site at https://
www.fda.gov/AdvisoryCommittees/
default.htm and scroll down to the
appropriate advisory committee meeting
link, or call the advisory committee
information line to learn about possible
modifications before coming to the
meeting.
SUPPLEMENTARY INFORMATION:
Food and Drug Administration
AGENCY:
The meeting will be held on
October 12, 2017, from 8:30 a.m. to 5
p.m.
DATES:
Agenda: On October 12, 2017, the
CTGTAC will meet in an open session
to discuss and make recommendations
on the safety and effectiveness of
biologics license application (BLA) for
voretigene neparvovec (BLA 125610),
submitted by Spark Therapeutics, Inc.
The proposed indication (use) for this
product is for the treatment of patients
with vision loss due to confirmed
biallelic RPE65 mutation-associated
retinal dystrophy.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
PO 00000
Frm 00027
Fmt 4703
Sfmt 4703
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee meeting
link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before October 4, 2017.
Oral presentations from the public will
be scheduled between approximately
11:15 a.m. and 12:15 p.m. Those
individuals interested in making formal
oral presentations should notify the
contact person and submit a brief
statement of the general nature of the
evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
requested to make their presentation on
or before September 26, 2017. Time
allotted for each presentation may be
limited. If the number of registrants
requesting to speak is greater than can
be reasonably accommodated during the
scheduled open public hearing session,
FDA may conduct a lottery to determine
the speakers for the scheduled open
public hearing session. The contact
person will notify interested persons
regarding their request to speak by
September 27, 2017.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with disabilities.
If you require accommodations due to a
disability, please contact Prabhakara
Atreya at least 7 days in advance of the
meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at:
https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
E:\FR\FM\28AUN1.SGM
28AUN1
Agencies
[Federal Register Volume 82, Number 165 (Monday, August 28, 2017)]
[Notices]
[Pages 40769-40770]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-18105]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF DEFENSE
GENERAL SERVICES ADMINISTRATION
NATIONAL AERONAUTICS AND SPACE ADMINISTRATION
[OMB Control No. 9000-0180; Docket No. 2017-0053; Sequence 12]
Information Collection; Affirmative Procurement of Biobased
Procurements Under Services and Construction Contracts
AGENCY: Department of Defense (DOD), General Services Administration
(GSA), and National Aeronautics and Space Administration (NASA).
ACTION: Notice of request for public comments regarding an extension to
an existing OMB clearance.
-----------------------------------------------------------------------
SUMMARY: Under the provisions of the Paperwork Reduction Act, the
Regulatory Secretariat Division (MVCB) will be submitting to the Office
of Management and Budget (OMB) a request to review and approve an
extension of a previously approved information collection requirement
regarding Biobased Procurements.
DATES: Submit comments on or before October 27, 2017.
ADDRESSES: Submit comments identified by Information Collection 9000-
0180, Affirmative Procurement of Biobased Procurements Under Services
and Construction Contracts, by any of the following methods:
Regulations.gov: https://www.regulations.gov. Submit
comments via the Federal eRulemaking portal by searching the OMB
control number 9000-0180. Select the link ``Comment Now'' that
corresponds with ``Information Collection 9000-0180, Affirmative
Procurement of Biobased Procurements Under Services and Construction
Contracts. Follow the instructions provided on the screen. Please
include your name, company name (if any), and ``Information Collection
9000-0180, ``Affirmative Procurement of Biobased Procurements Under
Services and Construction Contracts'' on your attached document.
Mail: General Services Administration, Regulatory
Secretariat Division (MVCB), 1800 F Street NW., Washington, DC 20405.
ATTN: Ms. Sosa/IC 9000-0180, Biobased Procurements.
Instructions: Please submit comments only and cite Information
Collection 9000-0180, Affirmative Procurement of Biobased Procurements
Under Services and Construction Contracts. Comments received generally
will be posted without change to https://www.regulations.gov, including
any personal and/or business confidential information provided. To
confirm receipt of your comment(s), please check www.regulations.gov,
approximately two to three days after submission to verify posting
(except allow 30 days for posting of comments submitted by mail).
FOR FURTHER INFORMATION CONTACT: Mr. Charles Gray, Procurement Analyst,
Office of Governmentwide Acquisition Policy, at telephone 703-795-6328,
or email charles.gray@gsa.gov.
SUPPLEMENTARY INFORMATION:
A. Purpose
Federal Acquisition Regulation clause 52.223-2, Affirmative
Procurement of Biobased Products Under Service and Construction
Contracts, requires prime contractors to report annually the product
types and dollar values of U.S. Department of Agriculture (USDA)-
designated biobased products purchased to the System for Award
Management (SAM) Web site. The information reported by prime
contractors enables Federal agencies to report annually to the Office
of Federal Procurement Policy (OFPP) concerning actions taken to
implement and measure progress in carrying out the preference for
biobased products required under section 9002 of the Farm Security and
Rural Investment Act of 2002, codified at 7 U.S.C. 8102.
B. Annual Reporting Burden
To determine the number of contractors performing construction and
service contracts that may involve the purchase of USDA-designated
biobased products, fiscal year 2016 data in the Federal Procurement
Data System (FPDS) was reviewed to calculate the number entities with
unique DUNS numbers that were awarded contracts for the following
selected Product Services Codes: A--Research and Development; F--
Natural Resources Management; J--Maintenance, Repair, and Rebuilding of
Equipment; M--Operation of Government-Owned Facility; S--Utilities and
Housekeeping Services; T--Photographic, Mapping, Printing, and
Publication Services; Y--Construction of Structures and Facilities; and
Z--Maintenance, Repair or Alteration of Real Property. The clause at
FAR 52.223-2 will apply to the majority of the contract actions in the
selected PSCs
The estimated total burden is as follows:
Respondents: 51,457.
Responses per Respondent: 5.
Total Annual Responses: 257,285.
[[Page 40770]]
Hours per Response: 5.
Total Burden Hours: 1,286,425.
Affected Public: Businesses or other for-profit and not-for-profit
institutions.
Frequency: Annually.
C. Public Comments
Public comments are particularly invited on: Whether this
collection of information is necessary for the proper performance of
functions of the FAR, and whether it will have practical utility;
whether our estimate of the public burden of this collection of
information is accurate, and based on valid assumptions and
methodology; ways to enhance the quality, utility, and clarity of the
information to be collected; and ways in which we can minimize the
burden of the collection of information on those who are to respond,
through the use of appropriate technological collection techniques or
other forms of information technology.
Obtaining Copies of Proposals: Requesters may obtain a copy of the
information collection documents from the General Services
Administration, Regulatory Secretariat Division (MVCB), 1800 F Street
NW., Washington, DC 20405, telephone 202-501-4755. Please cite OMB
Control No. 9000-0180, Affirmative Procurement of Biobased Procurements
Under Services and Construction Contracts, in all correspondence.
Dated: August 22, 2017.
Lorin S. Curit,
Director, Federal Acquisition Policy Division, Office of Government-
wide Acquisition Policy, Office of Acquisition Policy, Office of
Government-wide Policy.
[FR Doc. 2017-18105 Filed 8-25-17; 8:45 am]
BILLING CODE 6820-EP-P